

UC Berkeley

UC Berkeley Previously Published Works

Title

Correction to "Skeletal Editing of Pyrimidines to Pyrazoles by Formal Carbon Deletion"

Permalink

<https://escholarship.org/uc/item/9m07r5wd>

Journal

Journal of the American Chemical Society, 145(2)

ISSN

0002-7863

Authors

Bartholomew, G Logan
Carpaneto, Filippo
Sarpong, Richmond

Publication Date

2023-01-18

DOI

10.1021/jacs.2c13180

Supplemental Material

<https://escholarship.org/uc/item/9m07r5wd#supplemental>

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

Skeletal Editing of Pyrimidines to Pyrazoles by Formal Carbon Deletion

G. Logan Bartholomew, Filippo Carpaneto, and Richmond Sarpong*



Cite This: <https://doi.org/10.1021/jacs.2c10746>



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: A method for the conversion of pyrimidines into pyrazoles by a formal carbon deletion has been achieved guided by computational analysis. The pyrimidine heterocycle is the most common diazine in FDA-approved drugs, and pyrazoles are the most common diazole. An efficient method to convert pyrimidines into pyrazoles would therefore be valuable by leveraging the chemistries unique to pyrimidines to access diversified pyrazoles. One method for the conversion of pyrimidines into pyrazoles is known, though it proceeds in low yields and requires harsh conditions. The transformation reported here proceeds under milder conditions, tolerates a wide range of functional groups, and enables the simultaneous regioselective introduction of N-substitution on the resulting pyrazole. Key to the success of this formal one-carbon deletion method is a room-temperature triflylation of the pyrimidine core, followed by hydrazine-mediated skeletal remodeling.



INTRODUCTION

Of the top 200 selling U.S. FDA-approved drug compounds as of 2014, 59% contain at least one *N*-heterocycle.¹ While monoazacycles are the most prevalent,¹ di-azacycles also feature prominently. Of the latter, pyrimidines are the most common diazine (and the 6th most abundant *N*-heterocycle overall), and pyrazoles are the most common diazole.^{1–5} These heterocycles are privileged by virtue of the vectors they present for interactions (e.g., H-bonding) with biological targets⁴ and the numerous synthetic methods for their peripheral functionalization.^{6,7} Moreover, their late-stage peripheral diversification can accelerate the pace of drug and agrochemical discovery. This type of molecular editing⁸ can circumvent the need to effect a change on the periphery of a target heterocycle at the outset of a drug derivative synthesis or even a complete redesign of the route.

In comparison, direct, late-stage modifications of the core framework of heterocycles are challenging to accomplish. To expand the chemical space accessible from a given compound beyond peripheral modifications, interest in the skeletal editing of *N*-heterocycles (illustrated in Figure 2A) has increased in recent years.^{9–13} In combination with peripheral editing, the continued development of skeletal editing would facilitate the late stage, omnidirectional exploration of chemical space around a central molecule.

While pyrimidines are competent directing groups for peripheral functionalization by C–H functionalization (typically of substituents at C2 of the pyrimidine, *vide infra*),^{14–19} few methods for their skeletal editing are known (Figure 2B); however, reports describing the conversion of other hetero-

cycles into pyrimidines have begun to appear. Recently, Morandi and coworkers reported a nitrogen insertion into indole C–C bonds to generate quinazolines.²⁰ Similarly, Levin and coworkers recently disclosed an analogous carbene insertion into pyrazole N–N bonds to generate 2-aryl pyrimidines.²¹ Here, we report a reverse of the latter process—a method for the conversion of pyrimidines into pyrazoles by a formal carbon deletion (Figure 1B).

Unlike pyrimidines, pyrazoles are relatively poor directing groups for the C–H functionalization of their C-bound substituents, especially when the nitrogen adjacent to the substituent is itself substituted (Figure 2C,D).²² Because both NH- and N-functionalized pyrazoles are found in many biologically relevant molecules, we reasoned that a general, functional group tolerant method for the transformation of pyrimidines into pyrazoles would enable access to C–H functionalized pyrazole-containing compounds by leveraging the directing ability of the parent pyrimidine (Figure 2E). This example of skeletal editing would thus constitute a rapid diversification of the heterocyclic moiety and would complement typical peripheral diversification tactics.

Received: October 13, 2022




Figure 1. (A) Original disclosure of the hydrazine-mediated contraction of pyrimidine to pyrazole. (B) Summary of present disclosure.

In fact, such a transformation was reported in 1968, when van der Plas and Jongejan found that heating pyrimidine to 200 °C in the presence of solvent quantities of aqueous hydrazine affected its conversion to pyrazole, as outlined in Figure 1A. However, this reaction failed on substituted pyrimidines.²³ N-Methylation of the pyrimidine nitrogen by iodomethane lowered the LUMO of the pyrimidine ring such that the nucleophilic attack of hydrazine to effect the

contraction could occur at 100 °C, though the scope remained limited, and this two-step protocol required solvent quantities of iodomethane.

To broaden the scope of this transformation and generalize the conditions, we sought to achieve even more pronounced LUMO lowering of the pyrimidine unit in a one-pot process. Computations indicated that pyrimidine N-triflylation would sufficiently lower the pyrimidine LUMO (−3.88 vs −3.13 eV for N-Me pyridinium, corresponding to a difference of 13.98 kcal/mol; see the Supporting Information for details) to facilitate the nucleophilic attack of hydrazine at 23 °C. We experimentally confirmed triflic anhydride to be a competent equimolar activator. This discovery ultimately enabled the contraction of a broad range of substituted pyrimidines to the corresponding pyrazoles under mild conditions (Figure 1B). This formal carbon deletion converts the most prevalent diazine into the most common diazole found in FDA-approved pharmaceuticals. Importantly, the pyrimidine-to-pyrazole conversion sets the stage for using well-established pyrimidine-directed peripheral C–H functionalization for the diversification of the eventual pyrazole-containing products.

RESULTS AND DISCUSSION

We first sought to identify conditions for the catalytic activation of the pyrimidine core; however, no reactivity was observed using sub-stoichiometric amounts of Bronsted or Lewis acids, likely due to competing protonation or binding to the hydrazine nucleophile. We instead reasoned, with support from computations (see the Supporting Information for details), that successful activation might be achieved by N-acylation or N-sulfonylation.^{24–27} The activators evaluated on the basis of this hypothesis are summarized in Table 1. This investigation led to our discovery that triflylation of the





Figure 2. (A) Conceptual outline of peripheral and skeletal editing strategies. (B) Peripheral edits available about the pyrimidine heterocycle, including its use as a directing group for C–H functionalization. (C) Peripheral edits available for pyrazoles, noting its key inability to direct C–H functionalizations. (D) Rationale behind the poor directing group strength of pyrazoles relative to pyrimidines. ^aωB97x-D, 6-31G(d,p). (E) Conceptual outline to leverage both peripheral and skeletal editing to access C–H functionalized pyrazoles.

Table 1. Effect of Pyrimidine Activator


entry	activator	yield (%) ^a
1	BzCl	0
2	AcCl	0
3	EtOCOCl	0
4	PhOCOCl	17
5	1:1 PhOCOCl, NaI	62
6	MsCl	0
7	TsCl	0
8	Tf ₂ O	37
9 ^b	Tf ₂ O	72
10 ^c	Tf ₂ O	90

^aDetermined by ¹H NMR. ^b35 °C. ^cDioxane used as solvent.

pyrimidine nitrogen prior to addition of hydrazine effected the desired contraction in 37% yield at 23 °C (Table 1, entry 8). This preactivation stage is necessary to prevent hydrazine triflylation, which was found to be irreversible at temperatures up to 100 °C. A significant increase in yield to 72% was observed when the reaction was conducted at 35 °C (Table 1, entry 9); at this temperature, nucleophilic attack on the ring by

hydrazine could outcompete detriflylation (Figure 3A). A solvent screen led to the identification of anhydrous 1,4-dioxane as the optimal solvent, giving 5-phenyl-1H-pyrazole in 90% yield (Table 1, entry 10; see the Supporting Information for details). While water quenched the activated *N*-triflylpyrimidinium triflate species, exposure to air could not impede the reaction. Furthermore, *N*-triflylation could be quantitatively achieved at temperatures as low as −78 °C, reflected in the calculated low barrier of this step (Figure 3). As anticipated, hydrazine addition at −78 °C led to quantitative detriflylation of the *N*-triflylpyrimidinium species.

Mechanistically, as initially proposed by van Veldhuizen,²⁸ this transformation may proceed, as shown in Figure 3. *N*-Triflylation of the least sterically hindered (and most π -excessive) pyrimidine nitrogen ($\Delta G^\ddagger \approx 0.99$ kcal/mol; Figure 3A) serves to activate the pyrimidine ring toward nucleophilic attack (see the Supporting Information for details). The site-selectivity for *N*-triflylation is supported by the formation of 1-methyl-4-phenylpyrimidinium iodide (1a, Figure 3C) upon methylation of A and corroborated by the higher Fukui nucleophilicity index that was calculated for this atom (Figure 3D). The activated pyrimidinium is then attacked at C6 by hydrazine to give C. Computations found this step to be rate limiting, as shown in Figure 3. Detriflylation at this stage was found to be competitive at a lower temperature (Figure 3A), reflected in the yield increase when the reaction temperature




Figure 3. Mechanism of the triflylation-promoted, hydrazine-mediated ring contraction of pyrimidines. (A) Competitive detriflylation of B. (B) Calculations for amination collapse pathway. (C) X-ray crystal structure of *N*-methyl-4-phenylpyrimidinium iodide (MeCN molecule omitted for clarity). (D) Fukui nucleophilicity (left) and electrophilicity (right) indices for A and B, respectively.




Figure 4. Ring contraction scope. Reactions performed on 0.10 mmol of substrate. Percentages reported are isolated yields. (A) Scope of substrates substituted with arenes and heteroarenes at C4. (B) Scope of substrates substituted at C5. ^aTriflylation stage run at 60 °C for 2 h before the reaction mixture was cooled to 35 °C for the addition of hydrazine. (C) Scope of hydrazines. ^bHydrochloride salt of hydrazine derivative was used together with 4.0 equiv of Na₂CO₃. ^dThe products were isolated as a 3:1 N2/N1 substitution mixture.

was increased to 35 °C. Deprotonation of highly acidic hydrazinium species **C** gives **D**, followed by 6 π electrocyclic ring opening to give **E**. The barrier to electrocyclic ring opening from charged species **C** was calculated to be 16.18 kcal/mol higher than from neutral species **D**. Additionally, the barrier for aminal collapse from **D** was calculated to be 5.57 kcal/mol higher than 6 π electrocyclic ring opening from the same intermediate (Figure 3B). Thereafter, the terminal hydrazone nitrogen engages the ring-opened species (after tautomerization) at C4 to give charge-separated species **G**. Subsequent proton transfer to give **H** and elimination of *N*-triflylformamidine through a 1,5-sigmatropic H-shift results in the pyrazole product. In total, the reaction of 4-phenylpyrimidine (**A**) with hydrazine to give 5-phenyl-1*H*-pyrazole (**I**) and formamidine was calculated to be exergonic by 11.64 kcal/mol.

The scope of the formal carbon deletion is summarized in Figure 4. Because some substrates were observed to react more slowly than others, and product decomposition did not occur over prolonged reaction times, reactions were run over 18 h for consistency. The contraction protocol was found to be tolerant of electronically diverse arenes, as shown in Figure 4A

(compare yield for **2a** and **2b**). *Ortho*- and *meta*-phenyl derivatives displayed a similar trend (see **3a** and **3b**). Only a slight difference in yield was observed for *ortho*- and *meta*-methyl derivatives (see **4a** and **4b**). Halogenated substrates were tolerated as evidenced by the formation of **5a** and **5b** as well as **6a** and **6b**.

Heteroarene substitution on the pyrimidine ring was also well-tolerated. For example, **7** was formed in 81% yield. 4-(3-Pyridyl)pyrimidine and 4-pyrazinylpyrimidine, where competing triflylation of the heterocycle substituents was anticipated, contracted to **8a** and **8b** in poorer yields of 47% and 24%, respectively. Mass recovery in these cases was modest, and distinct competing reactivity was observed at the pyrazine unit. 2-Furyl and 2-thiophenyl derivatives also participated in the ring contraction, giving **9** and **10** in 56 and 87% yield, respectively.

Because directed C–H functionalization is often employed to introduce aromatic groups,^{15,29,30} we also evaluated the effect of biaryl substituents on the pyrimidine contraction. These results are summarized in Figure 4A. Contraction of a *para*-dimethylaminophenyl derivative led to **13** in a modest yield of 40%, possibly due to competing *N*-triflylation of the




Figure 5. (A,B) Scope of specialized substrates. ^a3.0 equiv Tf_2O was employed together with 4.0 equiv Na_2CO_3 ; the reaction mixture was stirred with 10.0 equiv aqueous NaOH in 2:1 1,4-dioxane:methanol (0.33 M) at 23 °C after completion to affect detriflylation. ^bThe basic workup step was omitted. (C) Scope of druglike substrates. ^cThe reaction was run at 60 °C. ^dHFIP was used as the reaction solvent, and triflylation was carried out at 0 °C. (D) Synthesis of a C–H functionalized late-stage intermediate of Celecoxib. (E) Demonstrative pyrimidine-directed C–H functionalization reactions.

more nucleophilic dimethylaniline nitrogen; 59% of the starting material was recovered in this case. A *para*-methoxyphenyl derivative gave **14** in an appreciable 65% yield, though some demethylation was observed. *meta*-Chlorophenyl and *para*-cyanophenyl derivatives gave **16** and **17** in 33 and 49% yield, respectively, along with a significant amount of recovered starting material.

We then sought to investigate the effect of functional groups appended directly to the pyrimidine ring. These results are summarized in Figure 4B. Hydrocarbon groups at C5 of the pyrimidine were well tolerated, giving yields of 50–88% (see **20**, **22**, or **23**). A fused pyrimidine participated readily, giving **28** in 88% yield. Steric encumbrance at C5 adversely affected the contraction; isopropyl appended **21** was formed in only 24% yield. Though electron rich polar groups were tolerated (e.g., methoxypyrazole **19** is formed in 60% yield), electron-deficient pyrimidines performed poorly (see **24–27**), likely due to incomplete triflylation or competing detriflylation of these substrates upon the addition of the hydrazine nucleophile. Heating these substrates to 60 °C for 2 h during the activation stage (to increase triflylation) then cooling to 35 °C prior to hydrazine introduction increased the yield significantly (e.g., from 9 to 53% for trifluoromethyl derivative **27**).

Because N1-functionalized pyrazoles, such as **31**, are incapable of directing C–H functionalizations (*vide supra*), we also evaluated the formation of N1-substituted pyrazoles

(Figure 4C). Phenylhydrazine provided N1-phenylpyrazole (**31**) in 50% yield, which was a lower yield than when unsubstituted hydrazine was used likely due to the *reduced* nucleophilicity of the phenyl-bearing nitrogen. The constitution of **31** is consistent with a faster initial attack of the terminal phenylhydrazine nitrogen. Phenylhydrazine hydrochloride derivatives also affected the contraction smoothly to give **30** and **32a–b** when excess Na_2CO_3 was added (see the Supporting Information for details). Notably, these hydrazines performed poorly in their free base forms. Electron-poor benzohydrazide contracted to **33** in 50% yield. A reverse in regioselectivity was observed when cyclohexylhydrazine was used as the contraction coupling partner, generating a 2.5:1 mixture of isomeric pyrazoles **34a–b** in 70% combined yield favoring substitution at N2 (confirmed by NOESY). This switch in selectivity likely arose from the *increased* nucleophilicity of the alkyl-bearing nitrogen in this case, favoring its initial addition to the activated pyrimidinium. C2-Aryl derivatives gave only trace amounts of the desired contraction products (see the Supporting Information for details). In these cases, because the C2-aryl group would be excised upon contraction, these substrates are not particularly well-aligned with the goal of diversification of substituted pyrimidines to afford the corresponding substituted pyrazoles.

We also modified the protocol so that the ring contraction could be carried out in the presence of free OH and NH groups (Figure 5A). To this end, transient OH triflylation was

achieved by using an excess of triflic anhydride along with Na_2CO_3 as an acid scavenger, enabling the contraction of an OH-containing pyrimidine to give **35** in 65% yield after basic workup (to unveil the *in situ*-triflylated phenol-OH). When the basic detriflylation step was omitted, *O*-triflylated product **36** was isolated in 61% yield along with **35** in 39% yield, presumably arising through hydrazine-mediated detriflylation of the phenol. This approach was applied to NH-containing 4-(*para*-aminophenyl)pyrimidine to give **37** in 47% yield along with a 33% recovery of starting material. A substituted quinazoline (a structural motif common in pharmaceuticals) contracted to give **38** in 41% yield (Figure 5B).

We also investigated the contraction of the pyrimidine group in complex molecules of pharmaceutical relevance, such as those shown in Figure 5C. Sterically hindered pyrimidine **39** (benzpyrimoxan)³¹ failed to undergo contraction under the typical conditions. However, the established protocol could be adapted to overcome the steric hindrance in **39** by increasing the reaction temperature to 60 °C, which led to a 20% yield of the desired contraction product. In comparison, the pyrimidine moiety of **40** readily underwent contraction in 57% yield with 41% starting material recovery.³² The successful contractions of **40**–**42** demonstrate the applicability of the method to C5-substituted pyrimidines. The agrochemical Fenarimol (**41**) underwent contraction in 37% yield along with 51% of the starting material recovered. Pyrimidinylated Rivaroxaban (Xarelto) derivative **42** underwent ring contraction in HFIP in 17% yield with 79% starting material recovery when triflylation carried was out at 0 °C. Notably, amidine-containing methylsulfinyl pyrimidine **43** underwent contraction in 65% yield with 31% starting material recovery. The successful contraction of this compound demonstrates that substrates bearing non-aryl C2-substitution can participate successfully in the transformation.

Finally, pyrimidine-directed C–H functionalization of **44** followed by contraction to the corresponding pyrazole gave a C–H functionalized derivative of Celecoxib (Celebrex) precursor **46**.³³ Specifically, pyrimidine-directed ruthenium-catalyzed C–H *bis*-arylation¹⁴ of **44** gave **45** in quantitative yield. Alternatively, directed C–H *mono*-arylation of **44** could be achieved in 75% yield (see the Supporting Information for details). Notably, no C–H functionalized products were formed under the same conditions with the analogous pyrazole substrate. Arylpyrimidine **45** underwent contraction to the corresponding pyrazole in 53% yield with 44% starting material recovery. The sequence shown in Figure 5D highlights the power of this transformation for heterocycle swaps, enabling the use of a pyrimidine as a surrogate for a pyrazole. Additionally, directed C–H functionalization reactions of 2-arylpyrimidines, such as *ortho*-acetoxylation¹⁷ and *ortho*-chlorination,³⁴ were successfully applied to 4-arylpyrimidine **44** to give **47** and **48** in good yields (Figure 5E; see the Supporting Information for details). Finally, in a large-scale demonstration, the contraction of 4-phenylpyrimidine was found to proceed in 80% yield on a 10.0 mmol (1.56 g) scale.

CONCLUSIONS

The approach reported here accomplishes the conversion of pyrimidines into pyrazoles under milder conditions and with a much broader substrate scope than was previously possible. While a pyrimidine to pyrazole conversion has been reported previously, it required high temperatures or methylation of the starting substrates with solvent quantities of the methylating

reagents, thus limiting the utility of that previously reported method. Furthermore, we have established a new platform for the preparation of diversified pyrazole compounds by leveraging the pyrimidine core as a strong directing group for C–H functionalization, which is then followed by scaffold hopping^{9,12,13} to the corresponding pyrazole. Our approach also provides access to a diverse range of N2-substituted pyrazoles, which are not easily accessed at a late stage due to the poor directing ability of these substituted diazoles in C–H functionalizations and the difficulty of their preparation through regioselective functionalization of substituted *NH*-pyrazoles. This report serves as a demonstration of the concept of “single atom” skeletal editing, examples of which continue to emerge.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/jacs.2c10746>.

Experimental procedures, characterization data, spectra for all new compounds, crystallographic data and Cartesian coordinates of DFT-optimized structures, and computational details (PDF)

Accession Codes

CCDC 2210673 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.

AUTHOR INFORMATION

Corresponding Author

Richmond Sarpong – Department of Chemistry, University of California, Berkeley, Berkeley, California 94720, United States; orcid.org/0000-0002-0028-6323; Email: rsarpong@berkeley.edu

Authors

G. Logan Bartholomew – Department of Chemistry, University of California, Berkeley, Berkeley, California 94720, United States

Filippo Carpaneto – Department of Chemistry, University of California, Berkeley, Berkeley, California 94720, United States; Present Address: Dipartimento di Chimica, Università degli Studi di Torino, Torino, 10124, Italia

Complete contact information is available at: <https://pubs.acs.org/10.1021/jacs.2c10746>

Funding

R.S. is grateful to the National Institute of General Medical Sciences (NIGMS R35 GM130345) for financial support. G. L. B. thanks the National Science Foundation for a graduate fellowship (NSF GRFP 2021294420). F. C. thanks Bio4-Dreams for funding a visiting student stay at UC Berkeley.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank Dr. Hasan Celik and UC Berkeley's NMR facility in the College of Chemistry (CoC-NMR) for spectroscopic assistance. Instruments in CoC-NMR are supported in part by

NIH S10OD024998. We thank Dr. Nicholas Settineri (UC Berkeley) for X-ray crystallographic studies of **1a**. We are grateful to Dr. Kathy Durkin and Dr. Dave Small for computational guidance. We are grateful to Prof. Dean Tantillo (UC Davis) for detailed and insightful discussions regarding the calculations described in Figure 3. The CoC-MGCF was supported in part by NIH S10OD023532. We thank Dr. Eric Simmons [BristolMyersSquibb Company, New Brunswick, NJ, USA (BMS)] for a gift of Rivaroxaban (the precursor to **42**). We thank Dr. Charles Yeung [Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD)] for a gift of **43**.

REFERENCES

- (1) Vitaku, E.; Smith, D. T.; Njardarson, J. T. Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals: Mini-perspective. *J. Med. Chem.* **2014**, *57*, 10257–10274.
- (2) Faria, J. V.; Vegi, P. F.; Migueta, A. G. C.; dos Santos, M. S.; Boechat, N.; Bernardino, A. M. R. Recently Reported Biological Activities of Pyrazole Compounds. *Bioorg. Med. Chem.* **2017**, *25*, 5891–5903.
- (3) Ansari, A.; Ali, A.; Asif, M.; Shamsuzzaman, S. Review: Biologically Active Pyrazole Derivatives. *New J. Chem.* **2017**, *41*, 16–41.
- (4) Kumar, S.; Narasimhan, B. Therapeutic Potential of Heterocyclic Pyrimidine Scaffolds. *Chem. Cent. J.* **2018**, *12*, 38.
- (5) Shearer, J.; Castro, J. L.; Lawson, A. D. G.; MacCoss, M.; Taylor, R. D. Rings in Clinical Trials and Drugs: Present and Future. *J. Med. Chem.* **2022**, *65*, 8699–8712.
- (6) Verbitskiy, E.; Rusinov, G.; Chupakhin, O.; Charushin, V. Recent Advances in Direct C–H Functionalization of Pyrimidines. *Synthesis* **2018**, *50*, 193–210.
- (7) Kang, E.; Kim, H. T.; Joo, J. M. Transition-Metal-Catalyzed C–H Functionalization of Pyrazoles. *Org. Biomol. Chem.* **2020**, *18*, 6192–6210.
- (8) Campos, K. R.; Coleman, P. J.; Alvarez, J. C.; Dreher, S. D.; Garbaccio, R. M.; Terrett, N. K.; Tillyer, R. D.; Truppo, M. D.; Parmee, E. R. The Importance of Synthetic Chemistry in the Pharmaceutical Industry. *Science* **2019**, *363*, No. eaat0805.
- (9) Roque, J. B.; Kuroda, Y.; Göttemann, L. T.; Sarpong, R. Deconstructive Diversification of Cyclic Amines. *Nature* **2018**, *564*, 244–248.
- (10) Kennedy, S. H.; Dherange, B. D.; Berger, K. J.; Levin, M. D. Skeletal Editing through Direct Nitrogen Deletion of Secondary Amines. *Nature* **2021**, *593*, 223–227.
- (11) Jurczyk, J.; Lux, M. C.; Adpressa, D.; Kim, S. F.; Lam, Y.; Yeung, C. S.; Sarpong, R. Photomediated Ring Contraction of Saturated Heterocycles. *Science* **2021**, *373*, 1004–1012.
- (12) Woo, J.; Christian, A. H.; Burgess, S. A.; Jiang, Y.; Mansoor, U. F.; Levin, M. D. Scaffold Hopping by Net Photochemical Carbon Deletion of Azaarenes. *Science* **2022**, *376*, 527–532.
- (13) Jurczyk, J.; Woo, J.; Kim, S. F.; Dherange, B. D.; Sarpong, R.; Levin, M. D. Single-Atom Logic for Heterocycle Editing. *Nat. Synth.* **2022**, *1*, 352–364.
- (14) Štefane, B.; Fabris, J.; Požgan, F. C–H Bond Functionalization of Arylpyrimidines Catalyzed by an in Situ Generated Ruthenium(II) Carboxylate System and the Construction of Tris(Heteroaryl)-Substituted Benzenes. *Eur. J. Org. Chem.* **2011**, *2011*, 3474–3481.
- (15) Norinder, J.; Matsumoto, A.; Yoshikai, N.; Nakamura, E. Iron-Catalyzed Direct Arylation through Directed C–H Bond Activation. *J. Am. Chem. Soc.* **2008**, *130*, 5858–5859.
- (16) Song, B.; Zheng, X.; Mo, J.; Xu, B. Palladium-Catalyzed Monoselective Halogenation of C–H Bonds: Efficient Access to Halogenated Arylpyrimidines Using Calcium Halides. *Adv. Synth. Catal.* **2010**, *352*, 329–335.
- (17) Zheng, X.; Song, B.; Xu, B. Palladium-Catalyzed Regioselective C–H Bond Ortho-Acetoxylation of Arylpyrimidines. *Eur. J. Org. Chem.* **2010**, 4376–4380.
- (18) Wang, X.; Truesdale, L.; Yu, J.-Q. Pd(II)-Catalyzed Ortho-Trifluoromethylation of Arenes Using TFA as a Promoter. *J. Am. Chem. Soc.* **2010**, *132*, 3648–3649.
- (19) Chatani, N.; Ie, Y.; Kakiuchi, F.; Murai, S. Ru₃(CO)₁₂-Catalyzed Reaction of Pyridylbenzenes with Carbon Monoxide and Olefins. Carbonylation at a C–H Bond in the Benzene Ring. *J. Org. Chem.* **1997**, *62*, 2604–2610.
- (20) Reisenbauer, J. C.; Green, O.; Franchino, A.; Finkelstein, P.; Morandi, B. Late-Stage Diversification of Indole Skeletons through Nitrogen Atom Insertion. *Science* **2022**, *377*, 1104–1109.
- (21) Hyland, E. E.; Kelly, P. Q.; McKillop, A. M.; Dherange, B. D.; Levin, M. D. Unified Access to Pyrimidines and Quinazolines Enabled by N–N Cleaving Carbon Atom Insertion. *J. Am. Chem. Soc.* **2022**, *144*, 19258–19264.
- (22) Xiao, X.; Jia, G.; Liu, F.; Ou, G.; Xie, Y. RuHCl(CO)(PPh₃)₃-Catalyzed Direct Amidation of Arene C–H Bond with Azides. *J. Org. Chem.* **2018**, *83*, 13811–13820.
- (23) van der Plas, H. C.; Jongejan, H. Ring Transformations in Reactions of Heterocyclic Compounds with Nucleophiles (III): Conversion of Pyrimidine and Some of Its Methyl Derivatives by Hydrazine and by Methylhydrazine Sulfate into Pyrazoles and Methylpyrazoles. *Recl. Trav. Chim. Pays-Bas* **1968**, *87*, 1065–1072.
- (24) Kuethe, J. T.; Comins, D. L. Addition of Indolyl and Pyrrolyl Grignard Reagents to 1-Acylpyridinium Salts. *J. Org. Chem.* **2004**, *69*, 2863–2866.
- (25) Kuethe, J. T.; Comins, D. L. Addition of Metallo Enolates to Chiral 1-Acylpyridinium Salts: Total Synthesis of (+)-Cannabistatine. *Org. Lett.* **2000**, *2*, 855–857.
- (26) Comins, D. L.; Abdullah, A. H. Regioselective Addition of Grignard Reagents to 1-Acylpyridinium Salts. A Convenient Method for the Synthesis of 4-Alkyl(Aryl)Pyridines. *J. Org. Chem.* **1982**, *47*, 4315–4319.
- (27) Comins, D. L.; Hong, H. The Addition of Metallo Enolates to Chiral 1-Acylpyridinium Salts. An Asymmetric Synthesis of (-)-Sedamine. *J. Org. Chem.* **1993**, *58*, 5035–5036.
- (28) Brouwer, M. S.; van der Plas, H. C.; van Veldhuizen, A. A NMR Study on the Ring Contraction of N-Methylpyrimidinium Salts into Pyrazoles. *Recl. Trav. Chim. Pays-Bas* **2010**, *97*, 110–112.
- (29) Štefane, B.; Fabris, J.; Požgan, F. C–H Bond Functionalization of Arylpyrimidines Catalyzed by an in Situ Generated Ruthenium(II) Carboxylate System and the Construction of Tris(Heteroaryl)-Substituted Benzenes. *Eur. J. Org. Chem.* **2011**, *2011*, 3474–3481.
- (30) Zhou, J.; Mao, Z.; Pan, H.; Zhang, X. Pd-Catalyzed Highly Selective and Direct Ortho C–H Arylation of Pyrrolo[2,3-*d*]pyrimidine Derivatives. *Org. Chem. Front.* **2020**, *7*, 324–328.
- (31) Satoh, E.; Kasahara, R.; Fukatsu, K.; Aoki, T.; Harayama, H.; Murata, T. Benzpyrimoxan: Design, Synthesis, and Biological Activity of a Novel Insecticide. *J. Pestic. Sci.* **2021**, *46*, 109.
- (32) Zhang, X.; Nottingham, K. G.; Patel, C.; Alegre-Requena, J. V.; Levy, J. N.; Paton, R. S.; McNally, A. Phosphorus-Mediated Sp²–Sp³ Couplings for C–H Fluoroalkylation of Azines. *Nature* **2021**, *594*, 217–222.
- (33) Gong, X.; Wang, R.; Zheng, J.; Feng, Y.; Kang, X. Synthesis Method of Celecoxib. CN 111484453 A, 2020.
- (34) Zhang, P.; Hong, L.; Li, G.; Wang, R. Sodium Halides as Halogenating Reagents: Rhodium(III)-Catalyzed Versatile and Practical Halogenation of Aryl Compounds. *Adv. Synth. Catal.* **2015**, *357*, 345–349.